Given that EphA2 can interact with HER2 (also named ErbB2) and cooperate with HER2 to activate ERK signaling [45], we concluded that RNF5 inhibition decreases ERK and Akt activation through the increase in the EphA2 level in HER2-negative breast cancer cells. Here, RNF5 is linked to breast carcinoma.